Activities of Transmitted/Founder and Chronic Clade B HIV-1 Vpu and a C-Terminal Polymorphism Specifically Affecting Virion Release
Acute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract these factors, and one such adaptation, the ability of Vpu to counteract BST2/tetherin, is associated with the evolution of simian immunodef...
Saved in:
Published in | Journal of virology Vol. 88; no. 9; pp. 5062 - 5078 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Microbiology
01.05.2014
|
Subjects | |
Online Access | Get full text |
ISSN | 0022-538X 1098-5514 1098-5514 |
DOI | 10.1128/JVI.03472-13 |
Cover
Abstract | Acute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract these factors, and one such adaptation, the ability of Vpu to counteract BST2/tetherin, is associated with the evolution of simian immunodeficiency virus (SIV
cpz
) into pandemic group M human immunodeficiency virus type 1 (HIV-1). During transmission between individuals, very few viruses or even a single virus, the “transmitted/founder” (T/F) virus, gives rise to the new infection, but in the new host the selective pressure of the immune response yields the diverse “quasispecies” of chronic infection. Here we examine the functional characteristics of Vpu proteins encoded by T/F viruses compared to acute and chronic viruses from longitudinally sampled subjects. The studied T/F Vpu proteins showed a trend toward optimized CD4 downregulation compared to chronic Vpu proteins but did not differ substantially in their ability to downregulate BST2 or enhance virion release, although individual clones from each group were impaired in these activities. Analysis of the functionally impaired clones identified a C-terminal residue, W76, as important specifically for Vpu enhancement of virion release. Primary Vpu clones encoding a W76G polymorphism, or site-directed mutants encoding a W76G substitution, were impaired in their ability to enhance virion release, but they were not defective for BST2 surface downregulation. Conversely, the virion release function of impaired primary clones was restored by creating a G76W substitution. The identification of W76 as important for virion release enhancement that is independent of BST2 surface downregulation supports the potential to mechanistically separate these functions of Vpu.
IMPORTANCE
To establish infection in a host, HIV-1 must evade the host's immune response, including the production of antiviral factors. HIV-1 encodes proteins that antagonize these defenses, including Vpu. Vpu counteracts the host protein BST2, which blocks the release of progeny viruses from the host cell. To determine the importance of Vpu activity to HIV-1 transmission, this study assessed the functionality of Vpu from viruses isolated soon after transmission (“transmitted/founder” viruses) compared to isolates from chronic infection. Although the anti-BST2 activity of Vpu proteins from the tested transmitted/founder viruses did not differ from the activity of the chronic Vpu proteins, the transmitted/founder Vpu proteins trended toward having superior activity against another host protein, CD4. Further, this study identified an amino acid near the C terminus of Vpu that is specifically important for Vpu's ability to enhance the release of progeny virus from the host cell, supporting the notion of a new mechanism for this function of Vpu. |
---|---|
AbstractList | Acute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract these factors, and one such adaptation, the ability of Vpu to counteract BST2/tetherin, is associated with the evolution of simian immunodeficiency virus (SIV
cpz
) into pandemic group M human immunodeficiency virus type 1 (HIV-1). During transmission between individuals, very few viruses or even a single virus, the “transmitted/founder” (T/F) virus, gives rise to the new infection, but in the new host the selective pressure of the immune response yields the diverse “quasispecies” of chronic infection. Here we examine the functional characteristics of Vpu proteins encoded by T/F viruses compared to acute and chronic viruses from longitudinally sampled subjects. The studied T/F Vpu proteins showed a trend toward optimized CD4 downregulation compared to chronic Vpu proteins but did not differ substantially in their ability to downregulate BST2 or enhance virion release, although individual clones from each group were impaired in these activities. Analysis of the functionally impaired clones identified a C-terminal residue, W76, as important specifically for Vpu enhancement of virion release. Primary Vpu clones encoding a W76G polymorphism, or site-directed mutants encoding a W76G substitution, were impaired in their ability to enhance virion release, but they were not defective for BST2 surface downregulation. Conversely, the virion release function of impaired primary clones was restored by creating a G76W substitution. The identification of W76 as important for virion release enhancement that is independent of BST2 surface downregulation supports the potential to mechanistically separate these functions of Vpu.
IMPORTANCE
To establish infection in a host, HIV-1 must evade the host's immune response, including the production of antiviral factors. HIV-1 encodes proteins that antagonize these defenses, including Vpu. Vpu counteracts the host protein BST2, which blocks the release of progeny viruses from the host cell. To determine the importance of Vpu activity to HIV-1 transmission, this study assessed the functionality of Vpu from viruses isolated soon after transmission (“transmitted/founder” viruses) compared to isolates from chronic infection. Although the anti-BST2 activity of Vpu proteins from the tested transmitted/founder viruses did not differ from the activity of the chronic Vpu proteins, the transmitted/founder Vpu proteins trended toward having superior activity against another host protein, CD4. Further, this study identified an amino acid near the C terminus of Vpu that is specifically important for Vpu's ability to enhance the release of progeny virus from the host cell, supporting the notion of a new mechanism for this function of Vpu. Acute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract these factors, and one such adaptation, the ability of Vpu to counteract BST2/tetherin, is associated with the evolution of simian immunodeficiency virus (SIVcpz) into pandemic group M human immunodeficiency virus type 1 (HIV-1). During transmission between individuals, very few viruses or even a single virus, the "transmitted/founder" (T/F) virus, gives rise to the new infection, but in the new host the selective pressure of the immune response yields the diverse "quasispecies" of chronic infection. Here we examine the functional characteristics of Vpu proteins encoded by T/F viruses compared to acute and chronic viruses from longitudinally sampled subjects. The studied T/F Vpu proteins showed a trend toward optimized CD4 downregulation compared to chronic Vpu proteins but did not differ substantially in their ability to downregulate BST2 or enhance virion release, although individual clones from each group were impaired in these activities. Analysis of the functionally impaired clones identified a C-terminal residue, W76, as important specifically for Vpu enhancement of virion release. Primary Vpu clones encoding a W76G polymorphism, or site-directed mutants encoding a W76G substitution, were impaired in their ability to enhance virion release, but they were not defective for BST2 surface downregulation. Conversely, the virion release function of impaired primary clones was restored by creating a G76W substitution. The identification of W76 as important for virion release enhancement that is independent of BST2 surface downregulation supports the potential to mechanistically separate these functions of Vpu. To establish infection in a host, HIV-1 must evade the host's immune response, including the production of antiviral factors. HIV-1 encodes proteins that antagonize these defenses, including Vpu. Vpu counteracts the host protein BST2, which blocks the release of progeny viruses from the host cell. To determine the importance of Vpu activity to HIV-1 transmission, this study assessed the functionality of Vpu from viruses isolated soon after transmission ("transmitted/founder" viruses) compared to isolates from chronic infection. Although the anti-BST2 activity of Vpu proteins from the tested transmitted/founder viruses did not differ from the activity of the chronic Vpu proteins, the transmitted/founder Vpu proteins trended toward having superior activity against another host protein, CD4. Further, this study identified an amino acid near the C terminus of Vpu that is specifically important for Vpu's ability to enhance the release of progeny virus from the host cell, supporting the notion of a new mechanism for this function of Vpu. Acute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract these factors, and one such adaptation, the ability of Vpu to counteract BST2/tetherin, is associated with the evolution of simian immunodeficiency virus (SIVcpz) into pandemic group M human immunodeficiency virus type 1 (HIV-1). During transmission between individuals, very few viruses or even a single virus, the "transmitted/founder" (T/F) virus, gives rise to the new infection, but in the new host the selective pressure of the immune response yields the diverse "quasispecies" of chronic infection. Here we examine the functional characteristics of Vpu proteins encoded by T/F viruses compared to acute and chronic viruses from longitudinally sampled subjects. The studied T/F Vpu proteins showed a trend toward optimized CD4 downregulation compared to chronic Vpu proteins but did not differ substantially in their ability to downregulate BST2 or enhance virion release, although individual clones from each group were impaired in these activities. Analysis of the functionally impaired clones identified a C-terminal residue, W76, as important specifically for Vpu enhancement of virion release. Primary Vpu clones encoding a W76G polymorphism, or site-directed mutants encoding a W76G substitution, were impaired in their ability to enhance virion release, but they were not defective for BST2 surface downregulation. Conversely, the virion release function of impaired primary clones was restored by creating a G76W substitution. The identification of W76 as important for virion release enhancement that is independent of BST2 surface downregulation supports the potential to mechanistically separate these functions of Vpu.UNLABELLEDAcute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract these factors, and one such adaptation, the ability of Vpu to counteract BST2/tetherin, is associated with the evolution of simian immunodeficiency virus (SIVcpz) into pandemic group M human immunodeficiency virus type 1 (HIV-1). During transmission between individuals, very few viruses or even a single virus, the "transmitted/founder" (T/F) virus, gives rise to the new infection, but in the new host the selective pressure of the immune response yields the diverse "quasispecies" of chronic infection. Here we examine the functional characteristics of Vpu proteins encoded by T/F viruses compared to acute and chronic viruses from longitudinally sampled subjects. The studied T/F Vpu proteins showed a trend toward optimized CD4 downregulation compared to chronic Vpu proteins but did not differ substantially in their ability to downregulate BST2 or enhance virion release, although individual clones from each group were impaired in these activities. Analysis of the functionally impaired clones identified a C-terminal residue, W76, as important specifically for Vpu enhancement of virion release. Primary Vpu clones encoding a W76G polymorphism, or site-directed mutants encoding a W76G substitution, were impaired in their ability to enhance virion release, but they were not defective for BST2 surface downregulation. Conversely, the virion release function of impaired primary clones was restored by creating a G76W substitution. The identification of W76 as important for virion release enhancement that is independent of BST2 surface downregulation supports the potential to mechanistically separate these functions of Vpu.To establish infection in a host, HIV-1 must evade the host's immune response, including the production of antiviral factors. HIV-1 encodes proteins that antagonize these defenses, including Vpu. Vpu counteracts the host protein BST2, which blocks the release of progeny viruses from the host cell. To determine the importance of Vpu activity to HIV-1 transmission, this study assessed the functionality of Vpu from viruses isolated soon after transmission ("transmitted/founder" viruses) compared to isolates from chronic infection. Although the anti-BST2 activity of Vpu proteins from the tested transmitted/founder viruses did not differ from the activity of the chronic Vpu proteins, the transmitted/founder Vpu proteins trended toward having superior activity against another host protein, CD4. Further, this study identified an amino acid near the C terminus of Vpu that is specifically important for Vpu's ability to enhance the release of progeny virus from the host cell, supporting the notion of a new mechanism for this function of Vpu.IMPORTANCETo establish infection in a host, HIV-1 must evade the host's immune response, including the production of antiviral factors. HIV-1 encodes proteins that antagonize these defenses, including Vpu. Vpu counteracts the host protein BST2, which blocks the release of progeny viruses from the host cell. To determine the importance of Vpu activity to HIV-1 transmission, this study assessed the functionality of Vpu from viruses isolated soon after transmission ("transmitted/founder" viruses) compared to isolates from chronic infection. Although the anti-BST2 activity of Vpu proteins from the tested transmitted/founder viruses did not differ from the activity of the chronic Vpu proteins, the transmitted/founder Vpu proteins trended toward having superior activity against another host protein, CD4. Further, this study identified an amino acid near the C terminus of Vpu that is specifically important for Vpu's ability to enhance the release of progeny virus from the host cell, supporting the notion of a new mechanism for this function of Vpu. Acute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract these factors, and one such adaptation, the ability of Vpu to counteract BST2/tetherin, is associated with the evolution of simian immunodeficiency virus (SIVcpz) into pandemic group M human immunodeficiency virus type 1 (HIV-1). During transmission between individuals, very few viruses or even a single virus, the "transmitted/founder" (T/F) virus, gives rise to the new infection, but in the new host the selective pressure of the immune response yields the diverse "quasispecies" of chronic infection. Here we examine the functional characteristics of Vpu proteins encoded by T/F viruses compared to acute and chronic viruses from longitudinally sampled subjects. The studied T/F Vpu proteins showed a trend toward optimized CD4 downregulation compared to chronic Vpu proteins but did not differ substantially in their ability to downregulate BST2 or enhance virion release, although individual clones from each group were impaired in these activities. Analysis of the functionally impaired clones identified a C-terminal residue, W76, as important specifically for Vpu enhancement of virion release. Primary Vpu clones encoding a W76G polymorphism, or site-directed mutants encoding a W76G substitution, were impaired in their ability to enhance virion release, but they were not defective for BST2 surface downregulation. Conversely, the virion release function of impaired primary clones was restored by creating a G76W substitution. The identification of W76 as important for virion release enhancement that is independent of BST2 surface downregulation supports the potential to mechanistically separate these functions of Vpu. IMPORTANCE To establish infection in a host, HIV-1 must evade the host's immune response, including the production of antiviral factors. HIV-1 encodes proteins that antagonize these defenses, including Vpu. Vpu counteracts the host protein BST2, which blocks the release of progeny viruses from the host cell. To determine the importance of Vpu activity to HIV-1 transmission, this study assessed the functionality of Vpu from viruses isolated soon after transmission ("transmitted/founder" viruses) compared to isolates from chronic infection. Although the anti-BST2 activity of Vpu proteins from the tested transmitted/founder viruses did not differ from the activity of the chronic Vpu proteins, the transmitted/founder Vpu proteins trended toward having superior activity against another host protein, CD4. Further, this study identified an amino acid near the C terminus of Vpu that is specifically important for Vpu's ability to enhance the release of progeny virus from the host cell, supporting the notion of a new mechanism for this function of Vpu. |
Author | Guatelli, John Jafari, Moein Lewinski, Mary K. |
Author_xml | – sequence: 1 givenname: Moein surname: Jafari fullname: Jafari, Moein organization: Department of Medicine, University of California, San Diego, La Jolla, California, USA – sequence: 2 givenname: John surname: Guatelli fullname: Guatelli, John organization: Department of Medicine, University of California, San Diego, La Jolla, California, USA, the VA San Diego Healthcare System, San Diego, California, USA – sequence: 3 givenname: Mary K. surname: Lewinski fullname: Lewinski, Mary K. organization: Department of Medicine, University of California, San Diego, La Jolla, California, USA, the VA San Diego Healthcare System, San Diego, California, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24574397$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkktv1DAURi1URKeFHWvkJQvS-pFMkg3SEFE6qBIIhhE7y7GvO0aOHeyk0qz7x-s-qACxYGVZ9_j42vc7Qgc-eEDoJSUnlLLm9ON2fUJ4WbOC8idoQUnbFFVFywO0IISxouLN90N0lNIPQmhZLstn6JCVVV3ytl6g65Wa7JWdLCQcDN5E6dNgpwn06VmYvYaIpde428XgrcKdkxrwO3y-3hYUb8f5ripxV2wgDtZLhz8Htx9CHHc2DfjrCMoaq6Rze7wyBvJt_hJvbbTB4y_gQCZ4jp4a6RK8eFiP0bez95vuvLj49GHdrS4KVTZ8KqRSSlJCOG3BsB76voeSqsrUrZbKNNoQTaUCYvqekkxw0oBmS920eddofoze3nvHuR9AK_BTlE6M0Q4y7kWQVvxZ8XYnLsOV4G3LG1ZnwesHQQw_Z0iTGGxS4Jz0EOYkaMUIbypCq_9A8yzYMksz-ur3th77-TWkDLy5B1QMKUUwjwgl4jYDImdA3GVA0Fsf-wtXdpJT_vD8KOv-fegGCES2yg |
CitedBy_id | crossref_primary_10_3390_v9100270 crossref_primary_10_1016_j_virol_2016_10_028 crossref_primary_10_1038_srep37225 crossref_primary_10_1016_j_jviromet_2016_11_004 crossref_primary_10_1128_JVI_02315_18 crossref_primary_10_1016_j_bbamem_2015_09_008 crossref_primary_10_1016_j_jbc_2021_101042 crossref_primary_10_1128_JVI_02736_15 crossref_primary_10_3389_fimmu_2017_01853 crossref_primary_10_3390_v7082824 crossref_primary_10_1073_pnas_1620144114 crossref_primary_10_3390_v14040808 crossref_primary_10_1128_mBio_00934_16 crossref_primary_10_1186_s12977_017_0343_8 crossref_primary_10_1128_JVI_01465_16 crossref_primary_10_1371_journal_pone_0120434 crossref_primary_10_3390_proteomes4010003 crossref_primary_10_1128_jvi_00176_22 crossref_primary_10_1016_j_celrep_2016_10_045 crossref_primary_10_3390_v14020406 crossref_primary_10_1128_JVI_00020_19 crossref_primary_10_1128_JVI_00504_16 crossref_primary_10_1038_srep09675 crossref_primary_10_1186_s12977_015_0192_2 crossref_primary_10_1371_journal_ppat_1005141 crossref_primary_10_1074_jbc_M114_630095 |
Cites_doi | 10.1016/j.chom.2009.05.008 10.1016/S0960-9822(99)80284-X 10.1128/JVI.06157-11 10.1073/pnas.0813223106 10.1128/JVI.03219-12 10.1097/00002030-199010000-00008 10.1093/nar/18.12.3587 10.1006/jmbi.1994.1542 10.1074/jbc.M111.296772 10.1016/S1097-2765(00)80056-8 10.1089/hum.1995.6.10-1291 10.1128/JVI.00242-09 10.1128/JVI.02272-12 10.1371/journal.ppat.1000856 10.1371/journal.ppat.1000429 10.1006/viro.1996.0491 10.1128/JVI.02660-07 10.1128/JVI.78.3.1069-1079.2004 10.1073/pnas.1304288110 10.1128/JVI.01795-10 10.1016/j.chom.2008.03.001 10.1016/j.jviromet.2006.06.019 10.1371/journal.ppat.1003299 10.1128/JVI.05933-11 10.1056/NEJMoa1110187 10.1128/JVI.05524-11 10.1086/512088 10.1038/nature06553 10.1128/JVI.01699-10 10.1084/jem.20090378 10.1038/381661a0 10.1016/j.tim.2010.06.010 10.1128/jvi.70.2.809-819.1996 10.1128/JVI.01844-08 10.1073/pnas.0802203105 10.1016/j.jtbi.2009.07.038 10.1371/journal.ppat.1000450 10.1128/jvi.59.2.284-291.1986 10.1128/jvi.64.2.621-629.1990 10.1371/journal.ppat.1000574 10.1186/1742-4690-7-13 10.1074/jbc.M300327200 10.7326/0003-4819-152-12-201006150-00005 10.1128/JVI.03230-13 10.1016/j.chom.2009.10.004 10.1074/jbc.274.47.33800 |
ContentType | Journal Article |
Copyright | Copyright © 2014, American Society for Microbiology. All Rights Reserved. 2014 American Society for Microbiology |
Copyright_xml | – notice: Copyright © 2014, American Society for Microbiology. All Rights Reserved. 2014 American Society for Microbiology |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7T2 7U9 C1K H94 5PM |
DOI | 10.1128/JVI.03472-13 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Health and Safety Science Abstracts (Full archive) Virology and AIDS Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AIDS and Cancer Research Abstracts Health & Safety Science Abstracts Virology and AIDS Abstracts Environmental Sciences and Pollution Management |
DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1098-5514 |
EndPage | 5078 |
ExternalDocumentID | PMC3993827 24574397 10_1128_JVI_03472_13 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIAID NIH HHS grantid: AI081668 – fundername: NIAID NIH HHS grantid: T32 AI007384 – fundername: NIAID NIH HHS grantid: P30 AI036214 – fundername: NIAID NIH HHS grantid: R37 AI081668 – fundername: NIAID NIH HHS grantid: AI036214 – fundername: NIAID NIH HHS grantid: P01 AI074621 – fundername: NIAID NIH HHS grantid: R01 AI081668 – fundername: NIAID NIH HHS grantid: AI74621 – fundername: NIAID NIH HHS grantid: R24 AI106039 |
GroupedDBID | --- -~X .55 .GJ 0R~ 18M 29L 2WC 39C 3O- 4.4 41~ 53G 5GY 5RE 5VS 6TJ 85S AAFWJ AAGFI AAYJJ AAYXX ABPPZ ACGFO ACNCT ADBBV ADXHL AENEX AFFNX AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CITATION CS3 D0S DIK E3Z EBS EJD F5P FRP GX1 H13 HYE HZ~ IH2 KQ8 MVM N9A O9- OHT OK1 P2P RHI RNS RPM RSF TR2 UPT VH1 W2D W8F WH7 WOQ X7M Y6R YQT ZGI ZXP ~02 ~KM CGR CUY CVF ECM EIF NPM PKN RHF UCJ 7X8 7T2 7U9 C1K H94 5PM |
ID | FETCH-LOGICAL-c483t-accca100319ef2bebbbe41c5f79dacf8df0d1ace0fbb10f2b308ed26d890f28d3 |
ISSN | 0022-538X 1098-5514 |
IngestDate | Thu Aug 21 13:48:23 EDT 2025 Fri Sep 05 14:28:14 EDT 2025 Fri Sep 05 10:07:13 EDT 2025 Wed Feb 19 02:42:35 EST 2025 Thu Apr 24 23:11:33 EDT 2025 Tue Jul 01 01:02:30 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c483t-accca100319ef2bebbbe41c5f79dacf8df0d1ace0fbb10f2b308ed26d890f28d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://jvi.asm.org/content/jvi/88/9/5062.full.pdf |
PMID | 24574397 |
PQID | 1514426273 |
PQPubID | 23479 |
PageCount | 17 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3993827 proquest_miscellaneous_1520385015 proquest_miscellaneous_1514426273 pubmed_primary_24574397 crossref_primary_10_1128_JVI_03472_13 crossref_citationtrail_10_1128_JVI_03472_13 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2014-05-01 |
PublicationDateYYYYMMDD | 2014-05-01 |
PublicationDate_xml | – month: 05 year: 2014 text: 2014-05-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
PublicationTitle | Journal of virology |
PublicationTitleAlternate | J Virol |
PublicationYear | 2014 |
Publisher | American Society for Microbiology |
Publisher_xml | – name: American Society for Microbiology |
References | e_1_3_2_26_2 e_1_3_2_27_2 e_1_3_2_28_2 e_1_3_2_29_2 e_1_3_2_41_2 e_1_3_2_40_2 e_1_3_2_20_2 e_1_3_2_43_2 e_1_3_2_21_2 e_1_3_2_42_2 e_1_3_2_22_2 e_1_3_2_45_2 e_1_3_2_23_2 e_1_3_2_44_2 e_1_3_2_24_2 e_1_3_2_47_2 e_1_3_2_25_2 e_1_3_2_46_2 e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_39_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_32_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_2_2 e_1_3_2_14_2 e_1_3_2_35_2 9660940 - Mol Cell. 1998 Mar;1(4):565-74 18342597 - Cell Host Microbe. 2008 Apr 17;3(4):245-52 20547906 - Ann Intern Med. 2010 Jun 15;152(12):778-85 8590733 - Hum Gene Ther. 1995 Oct;6(10):1291-7 16876264 - J Virol Methods. 2006 Oct;137(1):125-33 23323898 - N Engl J Med. 2013 Jan 17;368(3):218-30 19487424 - J Exp Med. 2009 Jun 8;206(6):1273-89 19196977 - Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2868-73 19660475 - J Theor Biol. 2009 Nov 21;261(2):341-60 22190722 - J Virol. 2012 Mar;86(5):2715-28 10375528 - Curr Biol. 1999 Jun 17;9(12):622-31 14722262 - J Virol. 2004 Feb;78(3):1069-79 20926557 - J Virol. 2010 Dec;84(24):12958-70 21849457 - J Virol. 2011 Oct;85(20):10659-68 23325684 - J Virol. 2013 Mar;87(6):3549-60 18256145 - J Virol. 2008 Apr;82(8):3952-70 19501037 - Cell Host Microbe. 2009 Jul 23;6(1):54-67 23221546 - J Virol. 2013 Feb;87(4):2046-57 19917496 - Cell Host Microbe. 2009 Nov 19;6(5):409-21 19515779 - J Virol. 2009 Aug;83(16):7931-47 19176632 - J Virol. 2009 Apr;83(8):3719-33 18200009 - Nature. 2008 Jan 24;451(7177):425-30 24352444 - J Virol. 2014 Mar;88(5):2633-44 20386718 - PLoS Pathog. 2010 Apr;6(4):e1000856 10559275 - J Biol Chem. 1999 Nov 19;274(47):33800-6 7520946 - J Mol Biol. 1994 Sep 2;241(5):651-62 19478868 - PLoS Pathog. 2009 May;5(5):e1000450 22090097 - J Virol. 2012 Jan;86(2):757-72 18490657 - Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7 2404139 - J Virol. 1990 Feb;64(2):621-9 23633949 - PLoS Pathog. 2013;9(4):e1003299 2194165 - Nucleic Acids Res. 1990 Jun 25;18(12):3587-96 8649511 - Nature. 1996 Jun 20;381(6584):661-6 23542380 - Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6626-33 3016298 - J Virol. 1986 Aug;59(2):284-91 8551619 - J Virol. 1996 Feb;70(2):809-19 8806575 - Virology. 1996 Sep 15;223(2):381-6 2261128 - AIDS. 1990 Oct;4(10):995-9 19730691 - PLoS Pathog. 2009 Sep;5(9):e1000574 19436700 - PLoS Pathog. 2009 May;5(5):e1000429 17330784 - J Infect Dis. 2007 Apr 1;195(7):951-9 20980512 - J Virol. 2011 Jan;85(1):51-63 20167081 - Retrovirology. 2010;7:13 20688520 - Trends Microbiol. 2010 Sep;18(9):388-96 22072710 - J Biol Chem. 2012 Jan 2;287(1):58-67 12746459 - J Biol Chem. 2003 Jul 25;278(30):28346-53 |
References_xml | – ident: e_1_3_2_16_2 doi: 10.1016/j.chom.2009.05.008 – ident: e_1_3_2_23_2 doi: 10.1016/S0960-9822(99)80284-X – ident: e_1_3_2_29_2 doi: 10.1128/JVI.06157-11 – ident: e_1_3_2_12_2 doi: 10.1073/pnas.0813223106 – ident: e_1_3_2_4_2 doi: 10.1128/JVI.03219-12 – ident: e_1_3_2_2_2 doi: 10.1097/00002030-199010000-00008 – ident: e_1_3_2_34_2 doi: 10.1093/nar/18.12.3587 – ident: e_1_3_2_35_2 doi: 10.1006/jmbi.1994.1542 – ident: e_1_3_2_42_2 doi: 10.1074/jbc.M111.296772 – ident: e_1_3_2_20_2 doi: 10.1016/S1097-2765(00)80056-8 – ident: e_1_3_2_44_2 doi: 10.1089/hum.1995.6.10-1291 – ident: e_1_3_2_9_2 doi: 10.1128/JVI.00242-09 – ident: e_1_3_2_38_2 doi: 10.1128/JVI.02272-12 – ident: e_1_3_2_10_2 doi: 10.1371/journal.ppat.1000856 – ident: e_1_3_2_15_2 doi: 10.1371/journal.ppat.1000429 – ident: e_1_3_2_19_2 doi: 10.1006/viro.1996.0491 – ident: e_1_3_2_27_2 doi: 10.1128/JVI.02660-07 – ident: e_1_3_2_39_2 doi: 10.1128/JVI.78.3.1069-1079.2004 – ident: e_1_3_2_46_2 doi: 10.1073/pnas.1304288110 – ident: e_1_3_2_11_2 doi: 10.1128/JVI.01795-10 – ident: e_1_3_2_6_2 doi: 10.1016/j.chom.2008.03.001 – ident: e_1_3_2_40_2 doi: 10.1016/j.jviromet.2006.06.019 – ident: e_1_3_2_13_2 doi: 10.1371/journal.ppat.1003299 – ident: e_1_3_2_41_2 doi: 10.1128/JVI.05933-11 – ident: e_1_3_2_47_2 doi: 10.1056/NEJMoa1110187 – ident: e_1_3_2_18_2 doi: 10.1128/JVI.05524-11 – ident: e_1_3_2_30_2 doi: 10.1086/512088 – ident: e_1_3_2_5_2 doi: 10.1038/nature06553 – ident: e_1_3_2_43_2 doi: 10.1128/JVI.01699-10 – ident: e_1_3_2_28_2 doi: 10.1084/jem.20090378 – ident: e_1_3_2_33_2 doi: 10.1038/381661a0 – ident: e_1_3_2_7_2 doi: 10.1016/j.tim.2010.06.010 – ident: e_1_3_2_37_2 doi: 10.1128/jvi.70.2.809-819.1996 – ident: e_1_3_2_3_2 doi: 10.1128/JVI.01844-08 – ident: e_1_3_2_25_2 doi: 10.1073/pnas.0802203105 – ident: e_1_3_2_26_2 doi: 10.1016/j.jtbi.2009.07.038 – ident: e_1_3_2_8_2 doi: 10.1371/journal.ppat.1000450 – ident: e_1_3_2_31_2 doi: 10.1128/jvi.59.2.284-291.1986 – ident: e_1_3_2_36_2 doi: 10.1128/jvi.64.2.621-629.1990 – ident: e_1_3_2_45_2 doi: 10.1371/journal.ppat.1000574 – ident: e_1_3_2_17_2 doi: 10.1186/1742-4690-7-13 – ident: e_1_3_2_21_2 doi: 10.1074/jbc.M300327200 – ident: e_1_3_2_32_2 doi: 10.7326/0003-4819-152-12-201006150-00005 – ident: e_1_3_2_24_2 doi: 10.1128/JVI.03230-13 – ident: e_1_3_2_14_2 doi: 10.1016/j.chom.2009.10.004 – ident: e_1_3_2_22_2 doi: 10.1074/jbc.274.47.33800 – reference: 23542380 - Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6626-33 – reference: 12746459 - J Biol Chem. 2003 Jul 25;278(30):28346-53 – reference: 19730691 - PLoS Pathog. 2009 Sep;5(9):e1000574 – reference: 10559275 - J Biol Chem. 1999 Nov 19;274(47):33800-6 – reference: 7520946 - J Mol Biol. 1994 Sep 2;241(5):651-62 – reference: 8590733 - Hum Gene Ther. 1995 Oct;6(10):1291-7 – reference: 18490657 - Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7 – reference: 18256145 - J Virol. 2008 Apr;82(8):3952-70 – reference: 22072710 - J Biol Chem. 2012 Jan 2;287(1):58-67 – reference: 2261128 - AIDS. 1990 Oct;4(10):995-9 – reference: 22190722 - J Virol. 2012 Mar;86(5):2715-28 – reference: 2194165 - Nucleic Acids Res. 1990 Jun 25;18(12):3587-96 – reference: 19501037 - Cell Host Microbe. 2009 Jul 23;6(1):54-67 – reference: 14722262 - J Virol. 2004 Feb;78(3):1069-79 – reference: 19478868 - PLoS Pathog. 2009 May;5(5):e1000450 – reference: 17330784 - J Infect Dis. 2007 Apr 1;195(7):951-9 – reference: 19436700 - PLoS Pathog. 2009 May;5(5):e1000429 – reference: 19487424 - J Exp Med. 2009 Jun 8;206(6):1273-89 – reference: 23633949 - PLoS Pathog. 2013;9(4):e1003299 – reference: 22090097 - J Virol. 2012 Jan;86(2):757-72 – reference: 2404139 - J Virol. 1990 Feb;64(2):621-9 – reference: 19176632 - J Virol. 2009 Apr;83(8):3719-33 – reference: 21849457 - J Virol. 2011 Oct;85(20):10659-68 – reference: 8806575 - Virology. 1996 Sep 15;223(2):381-6 – reference: 8551619 - J Virol. 1996 Feb;70(2):809-19 – reference: 23323898 - N Engl J Med. 2013 Jan 17;368(3):218-30 – reference: 20980512 - J Virol. 2011 Jan;85(1):51-63 – reference: 18200009 - Nature. 2008 Jan 24;451(7177):425-30 – reference: 8649511 - Nature. 1996 Jun 20;381(6584):661-6 – reference: 18342597 - Cell Host Microbe. 2008 Apr 17;3(4):245-52 – reference: 24352444 - J Virol. 2014 Mar;88(5):2633-44 – reference: 19917496 - Cell Host Microbe. 2009 Nov 19;6(5):409-21 – reference: 20386718 - PLoS Pathog. 2010 Apr;6(4):e1000856 – reference: 10375528 - Curr Biol. 1999 Jun 17;9(12):622-31 – reference: 20167081 - Retrovirology. 2010;7:13 – reference: 19196977 - Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2868-73 – reference: 19660475 - J Theor Biol. 2009 Nov 21;261(2):341-60 – reference: 20926557 - J Virol. 2010 Dec;84(24):12958-70 – reference: 23325684 - J Virol. 2013 Mar;87(6):3549-60 – reference: 20688520 - Trends Microbiol. 2010 Sep;18(9):388-96 – reference: 20547906 - Ann Intern Med. 2010 Jun 15;152(12):778-85 – reference: 19515779 - J Virol. 2009 Aug;83(16):7931-47 – reference: 3016298 - J Virol. 1986 Aug;59(2):284-91 – reference: 23221546 - J Virol. 2013 Feb;87(4):2046-57 – reference: 9660940 - Mol Cell. 1998 Mar;1(4):565-74 – reference: 16876264 - J Virol Methods. 2006 Oct;137(1):125-33 |
SSID | ssj0014464 |
Score | 2.25472 |
Snippet | Acute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 5062 |
SubjectTerms | Amino Acid Substitution Antigens, CD - biosynthesis Down-Regulation GPI-Linked Proteins - biosynthesis HIV Infections - virology HIV-1 - genetics HIV-1 - immunology HIV-1 - isolation & purification HIV-1 - physiology Host-Pathogen Interactions Human immunodeficiency virus 1 Human Immunodeficiency Virus Proteins - genetics Humans Longitudinal Studies Polymorphism, Genetic Simian immunodeficiency virus Viral Regulatory and Accessory Proteins - genetics Virus Release Virus-Cell Interactions |
Title | Activities of Transmitted/Founder and Chronic Clade B HIV-1 Vpu and a C-Terminal Polymorphism Specifically Affecting Virion Release |
URI | https://www.ncbi.nlm.nih.gov/pubmed/24574397 https://www.proquest.com/docview/1514426273 https://www.proquest.com/docview/1520385015 https://pubmed.ncbi.nlm.nih.gov/PMC3993827 |
Volume | 88 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKIiQuiDflJSPBKUo3z7V73K1YuoUihLpVb5GdOEukNq2WVqhc-Vv8OGbsPNwtINhL1CRuoub7OjOOZ-Yj5HXf4xH4ZeZKnsduxATYwRhVUxnEFzJVviexwHn88Wh4Ho1m8azT-WllLW3Wspd-_21dyXVQhWOAK1bJ_geyzUXhAHwGfGELCMP2nzA-TrX2Q2Eax2q3syjW-v3lqdZLUiZDsuqAiwqYmXJOnOHZ1PWd6WpjWrU6A3dicmLmmA-3XSzh4aN4hhanzxHG-RbXftA4lhfOtLhE0nwGj1Wv7eyHt1g_Z7-xH4lcmKr28VIVDSWBoron6NW04A_qW6OpPcbMvvc9-wWFH7XpgFZNABorKw11XLRtpmzzjDPjUGsNg3MyFhkbnmJYZ5tszi1q9i37G3uVbVfVrtEH2vcTAdY-jKZnPS-MWOCaeliLMquF5kwQxThjY623bHIYP40HGNzxgN0gNwPGdJLAu1mTYIQT7ajuVY8_qi67CPihfWNsR13dZTc22pvwXM3btQKhyV1yp4KYHhs63iMdVd4nt4ym6fYB-dGSki5zapHysKIkBdLRipJUU5KeUE1JCpTUZwVtKUltSlKbkrShJDWUpBUlH5Lz07eTwdCtlD7cNOLh2hUpGBIfHUxf5YFUUkoV-Wmcs34m0pxnuZf5IlVeLqXvwYjQ4yoLjjLehz2ehY_IQbks1RNChZf6CryUirmMYk9KLmKWeUyIFGL5OOgSp37GSVq1wUc1lnmip8MBTwCcRIOT-GGXvGlGr0z7lz-Me1XDlYB9xkU3Uarl5msCEXWEqg_sr2MCXKCHyLxLHhuIm7vV3OgStgN-MwD7w--eKYsvuk98Rc-n1_7mM3K7_UM_Jwfry416ATH4Wr7UVP8FFKng5g |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Activities+of+Transmitted%2FFounder+and+Chronic+Clade+B+HIV-1+Vpu+and+a+C-Terminal+Polymorphism+Specifically+Affecting+Virion+Release&rft.jtitle=Journal+of+virology&rft.au=Jafari%2C+Moein&rft.au=Guatelli%2C+John&rft.au=Lewinski%2C+Mary+K.&rft.date=2014-05-01&rft.pub=American+Society+for+Microbiology&rft.issn=0022-538X&rft.eissn=1098-5514&rft.volume=88&rft.issue=9&rft.spage=5062&rft.epage=5078&rft_id=info:doi/10.1128%2FJVI.03472-13&rft_id=info%3Apmid%2F24574397&rft.externalDocID=PMC3993827 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon |